PATRICIA MOORE: Open Payments
NPI 1871502112 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,341 in 116 payments from 21 companies in 2025. Trend: 2023 $2,696 · 2024 $2,469 · 2025 $2,341
Food & beverage: $2,341
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $529 |
| Janssen Biotech, Inc. | 26 | $413 |
| Ipsen Biopharmaceuticals, Inc | 5 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $183 |
| Lilly USA, LLC | 8 | $157 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $143 |
| Celltrion USA Inc. | 5 | $116 |
| Ardelyx, Inc. | 4 | $91 |
| Gilead Sciences, Inc. | 4 | $84 |
| Janssen Scientific Affairs, LLC | 1 | $62 |
Products named: TREMFYA, LINZESS, IQIRVO, RINVOQ, OMVOH, XIFAXAN, VEGZELMA, IBSRELA.
Industry payments across TX — which companies pay providers there.
